Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)

Fabio Facchinetti; Maria Salome Bezerra Espinola; Didier Dewailly; Ali Cenk Ozay; Nikos Prapas; Mónica Vazquez-Levin; Artur Wdowiak; Vittorio Unfer; Expert Group on Inositols in Preclinical and Clinical Research

doi:10.1016/j.tem.2020.04.003

Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)

Trends Endocrinol Metab. 2020 Aug;31(8):570-579. doi: 10.1016/j.tem.2020.04.003. Epub 2020 May 15.

Authors

Fabio Facchinetti¹, Maria Salome Bezerra Espinola², Didier Dewailly³, Ali Cenk Ozay⁴, Nikos Prapas⁵, Mónica Vazquez-Levin⁶, Artur Wdowiak⁷, Vittorio Unfer⁸; Expert Group on Inositols in Preclinical and Clinical Research

Collaborators

Expert Group on Inositols in Preclinical and Clinical Research:
Fabio Facchinetti⁹, Vittorio Unfer¹⁰, Marialuisa Appetecchia¹¹, Cesare Aragona², Matteo Bertelli¹², Arturo Bevilacqua¹³, Maria Salome Bezerra Espinola², Mariano Bizzarri¹⁴, Pietro Cavalli¹⁵, Andrew Copp¹⁶, Rosario D'Anna¹⁷, Didier Dewailly¹⁸, Nicholas Greene¹⁶, Imelda Hernández Marín¹⁹, Zdravko A Kamenov²⁰, Eleni Kandaraki²¹, Evanthia Diamanti-Kandarakis²¹, Antonio Simone Laganà²², Giovanni Monastra²³, Mario Montanino Oliva²⁴, John E Nestler²⁵, Ali Cenk Ozay⁴, Olga Papalou²¹, Lali Pkhaladze²⁶, Giusy Porcaro²⁷, Nikos Prapas²⁸, Christophe O Soulage²⁹, Annarita Stringaro³⁰, Mónica Vazquez-Levin⁶, Artur Wdowiak⁷

Affiliations

¹ Mother-Infant Department, University of Modena and Reggio Emilia, Modena, Italy.
² Systems Biology Laboratory, Department of Experimental Medicine, Sapienza University, Rome, Italy.
³ Faculty of Medicine, University of Lille, and Institut National de la Santé et de la Recherche Médicale (INSERM) Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, Lille, France.
⁴ Near East University, Faculty of Medicine, Department of Obstetrics and Gynecology, and Research Center of Experimental Health Sciences, Nicosia, Cyprus.
⁵ Third Department of OB-GYNAE, Aristotle University of Thessaloniki, and IVF Laboratory, IAKENTRO Fertility Centre, Thessaloniki, Greece.
⁶ National Council of Scientific and Technical Research, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina.
⁷ Diagnostic Techniques Unit, Medical University of Lublin, Poland.
⁸ Department of Experimental Medicine, Sapienza University, Rome, Italy. Electronic address: vunfer@gmail.com.
⁹ Department of Obstetrics and Gynecology and Pediatrics, University of Modena and Reggio Emilia, Modena, Italy.
¹⁰ Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
¹¹ Oncological Endocrinology Unit, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
¹² EBTNA Laboratory, Via Delle Maioliche 57/G, and MAGI Laboratory, Via Delle Maioliche, 57/D, 38068 Rovereto, TN, Italy.
¹³ Department of Dynamic and Clinical Psychology, Sapienza University, Rome, Italy.
¹⁴ Department of Experimental Medicine, Systems Biology Group, University La Sapienza, Rome, Italy.
¹⁵ Clinical Genetics, ASST Cremona, Cremona, Italy.
¹⁶ Newlife Birth Defects Research Centre and Developmental Biology and Cancer Programme, Institute of Child Health, University College London, London, UK.
¹⁷ Department of Human Pathology, University of Messina, Messina, Italy.
¹⁸ Faculty of Medicine, University of Lille, and INSERM Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, Lille, France.
¹⁹ Human Reproduction Department, Hospital Juárez de México, and Universidad Nacional Autónoma de México (UNAM), México City, México.
²⁰ Department of Internal Medicine, Medical University of Sofia, Sofia, Bulgaria.
²¹ Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, Athens, Greece.
²² Department of Obstetrics and Gynecology, 'Filippo Del Ponte' Hospital, University of Insubria, Varese, Italy.
²³ Systems Biology Laboratory, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
²⁴ Department of Obstetrics and Gynecology, Santo Spirito Hospital, Rome, Italy.
²⁵ Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
²⁶ Ioseb Zhordania Institute of Reproductology, Tbilisi, Georgia.
²⁷ Women's Health Center, USL, Umbria, 2, Orvieto, Italy.
²⁸ Third department of OB-GYNAE, and IVF Laboratory, IAKENTRO Fertility Centre, Thessaloniki, Greece.
²⁹ University of Lyon, INSERM U1060, CarMeN, INSA de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
³⁰ National Center for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy.

PMID: 32418772
DOI: 10.1016/j.tem.2020.04.003

Abstract

It is well known that myo-inositol (MI) and D-chiro-inositol (DCI) are insulin-sensitizing agents, and MI is of proven utility in polycystic ovary syndrome (PCOS). In addition, MI plays a pivotal role in the physiology of reproduction, and has beneficial effects on the development of oocytes, spermatozoa, and embryos. By contrast, DCI has little effect on spermatozoa, but high concentrations in the ovary can negatively affect the quality of oocytes and the blastocyst. Overall, the evidence in the literature supports the beneficial effects of MI in both female and male reproduction, warranting clinical use of MI in assisted reproductive treatment (ART).

Keywords: D-chiro-inositol, polycystic ovary syndrome; assisted reproductive treatment; in vitro fertilization; infertility; myo-inositol.

Publication types

Review

MeSH terms

Female
Fertilization in Vitro / methods
Humans
Inositol / therapeutic use*
Male
Polycystic Ovary Syndrome / drug therapy
Reproductive Techniques, Assisted*

Substances

Inositol